Biocon stock settles 5% higher after US drug regulator clears Bengaluru API facility unit, stock up 35% YTD | Stock Market News
Source: Live Mint
Biocon stock price: Shares of Biocon extended gains to settle five per cent higher on Tuesday, December 24 after the United States Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) with a Voluntary Action Status (VAI) for its Active Pharmaceutical Ingredients (API) facility in Bengaluru.
